Oral myostatin inhibitor therapeutic - PeptiDream/Kawasaki Medical School
Latest Information Update: 10 Mar 2025
At a glance
- Originator Kawasaki Medical School; PeptiDream
- Class Obesity therapies; Peptides
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy; Muscular disorders; Obesity; Spinal muscular atrophy
Most Recent Events
- 10 Mar 2025 Preclinical trials in Duchenne muscular dystrophy is underway in Japan (SC) (PeptiDream pipeline, March 2025)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Japan (PO)
- 04 Feb 2025 Preclinical trials in Muscular disorders in Japan (PO), prior to February 2025 (Peptidream pipeline, February 2025)